Biosimilar Launch Strategy: Reinforce Safety Profiles In Asia – BIO Conference
This article was originally published in PharmAsia News
Executive Summary
ATLANTA - When organizers titled the "Asia as the Biosimilar Launch Pad" session at BIO, they meant it. Many of the panelists agreed that a good strategy for launching biosimilars in the U.S. is to first release the product in Asia or emerging markets to create a stronger safety profile for the U.S. approval application
You may also be interested in...
Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.
Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.
Biopharma Industry Slated As China Pillar Industry, But Key Domestic Support Missing
SHANGHAI - Biopharmaceuticals will take a share in the Chinese central government's RMB 62.8 billion ($9.18 billion) investment plan to facilitate 11 key projects during 2009 to 2010. China's State Council passed a policy in May to promote the biotech industry to develop it as one of China's pillar industries in the future